Intercept Pharmaceuticals, Inc. (ICPT)’s Stock Insider Trade – Francesco Micheli Made a Purchase of 390,625 Shares; Platinum Investment Management LTD Cut Its Foundation Medicine (FMI) Holding

April 10, 2018 - By rebbecca

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Platinum Investment Management Ltd decreased Foundation Medicine Inc (FMI) stake by 41.68% reported in 2017Q4 SEC filing. Platinum Investment Management Ltd sold 37,800 shares as Foundation Medicine Inc (FMI)’s stock rose 20.73%. The Platinum Investment Management Ltd holds 52,900 shares with $3.61 million value, down from 90,700 last quarter. Foundation Medicine Inc now has $2.77 billion valuation. The stock increased 5.17% or $3.7 during the last trading session, reaching $75.2. About 246,065 shares traded. Foundation Medicine, Inc. (NASDAQ:FMI) has risen 134.36% since April 10, 2017 and is uptrending. It has outperformed by 122.81% the S&P500.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals has $423 highest and $45.0 lowest target. $154.49’s average target is 123.12% above currents $69.24 stock price. Intercept Pharmaceuticals had 73 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Perform” rating by Oppenheimer on Friday, September 22. The company was maintained on Thursday, November 16 by Wedbush. As per Wednesday, November 1, the company rating was upgraded by Laidlaw. The rating was maintained by Wedbush on Wednesday, June 1 with “Outperform”. The rating was maintained by Goldman Sachs on Tuesday, May 31 with “Neutral”. JMP Securities downgraded the shares of ICPT in report on Wednesday, October 4 to “Market Perform” rating. The stock has “Mkt Perform” rating by FBR Capital on Wednesday, November 11. As per Friday, December 4, the company rating was initiated by Wells Fargo. The stock has “Buy” rating by BMO Capital Markets on Friday, July 21. The stock has “Buy” rating by Credit Suisse on Monday, January 22.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on May, 3. They expect $-3.42 earnings per share, up 5.26% or $0.19 from last year’s $-3.61 per share. After $-4.43 actual earnings per share reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.80% EPS growth.

The stock decreased 3.30% or $2.36 during the last trading session, reaching $69.24. About 796,424 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since April 10, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

390,625 shares of Intercept Pharmaceuticals Inc were acquired by Francesco Micheli , the company’s shareholder. The shares are valued at $25.00 million which has been calculated on the basis of the average transactions stock price ($64.0 of a share). This investment was reported on April 9, 2018 and is already filed with the Washington-based SEC. The legal report is accessible for free to the public here. The regulatory filing shows that Francesco Micheli now possess about 27.19% of the New York-based company’s market capitalization (total value of the shares outstanding)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $1.74 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.02, from 1.33 in 2017Q3. It is negative, as 19 investors sold Intercept Pharmaceuticals, Inc. shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. Dsc Advsrs L P reported 3,500 shares. Teacher Retirement Systems Of Texas owns 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 5,929 shares. Parametric Portfolio Lc has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Axa has 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 24,632 shares. Eulav Asset Mngmt invested 0.18% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Altrinsic Global Advsrs Limited Co accumulated 310,300 shares or 0.7% of the stock. New York-based Kazazian Asset Mgmt has invested 0.31% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Global X Limited Liability Corp, a New York-based fund reported 286 shares. Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 4,224 shares. Credit Suisse Ag stated it has 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). State Of Alaska Department Of Revenue owns 1,600 shares for 0% of their portfolio. 1,633 are owned by Pnc Fincl Serv Gp. Voloridge Inv Management Ltd Llc owns 0.02% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 16,424 shares. State Board Of Administration Of Florida Retirement System holds 25,522 shares or 0% of its portfolio. Regal Advisors Lc has invested 0.39% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Analysts await Foundation Medicine, Inc. (NASDAQ:FMI) to report earnings on May, 8. They expect $-1.06 earnings per share, up 19.08% or $0.25 from last year’s $-1.31 per share. After $-1.05 actual earnings per share reported by Foundation Medicine, Inc. for the previous quarter, Wall Street now forecasts 0.95% negative EPS growth.

Investors sentiment increased to 1.39 in 2017 Q4. Its up 0.11, from 1.28 in 2017Q3. It improved, as 13 investors sold FMI shares while 28 reduced holdings. 33 funds opened positions while 24 raised stakes. 10.07 million shares or 3.72% more from 9.71 million shares in 2017Q3 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) holds 10,378 shares. First Advisors Lp holds 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 28,432 shares. Ubs Asset Mgmt Americas Incorporated invested 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). The California-based Parallax Volatility Advisers Ltd Partnership has invested 0% in Foundation Medicine, Inc. (NASDAQ:FMI). Principal Financial Grp invested in 5,891 shares. Great West Life Assurance Communications Can accumulated 1,700 shares. Laurion Management LP holds 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 3,288 shares. Strs Ohio stated it has 13,700 shares or 0% of all its holdings. Lord Abbett And Co Limited Com accumulated 595,515 shares. Moreover, Karp Cap Management Corp has 0.36% invested in Foundation Medicine, Inc. (NASDAQ:FMI). Geode Ltd Liability holds 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 161,420 shares. Moreover, Dekabank Deutsche Girozentrale has 0.01% invested in Foundation Medicine, Inc. (NASDAQ:FMI). State Street Corporation reported 450,307 shares. Group owns 9,754 shares. State Common Retirement Fund holds 0% or 16,300 shares in its portfolio.

Among 11 analysts covering Foundation Medicine (NASDAQ:FMI), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Foundation Medicine had 16 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Thursday, July 30 by JMP Securities. The rating was maintained by Wells Fargo on Thursday, March 8 with “Market Perform”. Cowen & Co initiated Foundation Medicine, Inc. (NASDAQ:FMI) rating on Thursday, February 15. Cowen & Co has “Buy” rating and $90.0 target. The firm earned “Buy” rating on Monday, September 14 by BTIG Research. Cowen & Co maintained the stock with “Buy” rating in Wednesday, March 28 report. The firm has “Neutral” rating given on Wednesday, November 4 by BTIG Research. On Wednesday, September 21 the stock rating was maintained by UBS with “Neutral”. The firm has “Hold” rating given on Thursday, November 3 by Benchmark. The rating was upgraded by BTIG Research on Monday, May 15 to “Buy”. On Wednesday, September 16 the stock rating was downgraded by Wells Fargo to “Market Perform”.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart